Use of 33P for Sanger DNA sequencing

The use of [alpha-33P]deoxyadenosine 5'-triphosphate ([alpha-33P]dATP) in DNA sequencing has been described. 33P has a maximum beta-emission energy that is 50% stronger than 35S, but fivefold weaker than 32P. As a result, sequences generated using [alpha-33P]dATP have short exposure times like...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:BioTechniques. - 1988. - 11(1991), 1 vom: 15. Juli, Seite 36, 38
1. Verfasser: Zagursky, R J (VerfasserIn)
Weitere Verfasser: Conway, P S, Kashdan, M A
Format: Aufsatz
Sprache:English
Veröffentlicht: 1991
Zugriff auf das übergeordnete Werk:BioTechniques
Schlagworte:Journal Article Deoxyadenine Nucleotides Phosphorus Radioisotopes DNA 9007-49-2 2'-deoxyadenosine triphosphate K8KCC8SH6N
LEADER 01000caa a22002652 4500
001 NLM019353944
003 DE-627
005 20250125061131.0
007 tu
008 231221s1991 xx ||||| 00| ||eng c
028 5 2 |a pubmed25n0065.xml 
035 |a (DE-627)NLM019353944 
035 |a (NLM)1954015 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Zagursky, R J  |e verfasserin  |4 aut 
245 1 0 |a Use of 33P for Sanger DNA sequencing 
264 1 |c 1991 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 02.01.1992 
500 |a Date Revised 23.11.2016 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a The use of [alpha-33P]deoxyadenosine 5'-triphosphate ([alpha-33P]dATP) in DNA sequencing has been described. 33P has a maximum beta-emission energy that is 50% stronger than 35S, but fivefold weaker than 32P. As a result, sequences generated using [alpha-33P]dATP have short exposure times like 32P, yet they maintain band resolution similar to 35S. Handling of [alpha-33P]dATP is straightforward because no special lead or Plexiglas shielding is necessary 
650 4 |a Journal Article 
650 7 |a Deoxyadenine Nucleotides  |2 NLM 
650 7 |a Phosphorus Radioisotopes  |2 NLM 
650 7 |a DNA  |2 NLM 
650 7 |a 9007-49-2  |2 NLM 
650 7 |a 2'-deoxyadenosine triphosphate  |2 NLM 
650 7 |a K8KCC8SH6N  |2 NLM 
700 1 |a Conway, P S  |e verfasserin  |4 aut 
700 1 |a Kashdan, M A  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t BioTechniques  |d 1988  |g 11(1991), 1 vom: 15. Juli, Seite 36, 38  |w (DE-627)NLM012627046  |x 0736-6205  |7 nnns 
773 1 8 |g volume:11  |g year:1991  |g number:1  |g day:15  |g month:07  |g pages:36, 38 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_21 
912 |a GBV_ILN_22 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_60 
912 |a GBV_ILN_62 
912 |a GBV_ILN_65 
912 |a GBV_ILN_70 
912 |a GBV_ILN_99 
912 |a GBV_ILN_121 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_350 
912 |a GBV_ILN_618 
912 |a GBV_ILN_640 
912 |a GBV_ILN_754 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2002 
912 |a GBV_ILN_2003 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2006 
912 |a GBV_ILN_2007 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2009 
912 |a GBV_ILN_2010 
912 |a GBV_ILN_2012 
912 |a GBV_ILN_2015 
912 |a GBV_ILN_2018 
912 |a GBV_ILN_2023 
912 |a GBV_ILN_2035 
912 |a GBV_ILN_2040 
912 |a GBV_ILN_2060 
912 |a GBV_ILN_2099 
912 |a GBV_ILN_2105 
912 |a GBV_ILN_2121 
912 |a GBV_ILN_2470 
951 |a AR 
952 |d 11  |j 1991  |e 1  |b 15  |c 07  |h 36, 38